Katie Suzanne Traylor DO, Presenter: Nothing to Disclose

Erin E. Grady MD, Abstract Co-Author: Nothing to Disclose

1) Review the clinical impact of prostate cancer. 2) Learn the value of bone scanning techniques in patients with prostate cancer. 3) Review palliative radionuclide therapies with Samarium-153 EDTMP and Strontium-89 chloride. 4) Learn about the newly FDA approved Radium-223 dichloride treatment for osseous metastatic disease with prostate cancer and how it improves overall survival.

• Prostate cancer demographics in the United States and world • Assessment of progression of disease with the utilization of whole body bone scanning with 99mTc MDP and whole body bone scanning with 18F sodium fluoride PET • ACR Appropriateness criteria • NCCN guidelines • NOPR • Palliative therapies with 153Sm EDTMP and 89Sr chloride discussing the indications, safe use of tje therapy course of palliative radionuclides, as well as, the radiation safety consideration. • 223Ra dichloride alpha particle therapy, indications for the therapy and NCCN guidelines • NCCN guidelines including the ALSYMPCA trial results, safe use of 223Ra, the therapy course and radiation therapy considerations

http://abstract.rsna.org/uploads/2014/14015609/14015609_1xav.pdf

Traylor, K, Grady, E, Targeted Molecular Imaging and Therapy for Metastatic Prostate Cancer.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015609.html